telavancin and Endocarditis

Infective endocarditis (IE) one-year mortality rates approach 40%. Here, we report two native valve Enterococcus faecalis IE cases in patients successfully treated with telavancin. An 88-year-old with mitral valve endocarditis and a penicillin allergy, initially treated with intravenous vancomycin, was switched to telavancin. A 69-year-old, who previously received amoxicillin and intravenous vancomycin for presumed enterococcal bacteraemia, was diagnosed with dual valve endocarditis for which he received telavancin. Both received six weeks of telavancin. Neither had telavancin-related adverse events, evidence of infection at six months, nor required telavancin dosing adjustments. Documented use of novel treatments for serious enterococcal infections is needed.

Topics: Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Endocarditis; Enterococcus faecalis; Female; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Male; Salvage Therapy; Treatment Outcome

Emerging infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) isolates are more likely to be associated with treatment failures than infections caused by other types of S. aureus. We present a case of pacemaker lead infective endocarditis caused by a non-daptomycin-susceptible strain of VISA. After 8 weeks of parenteral telavancin therapy, the patient achieved microbiological and clinical cure.

Topics: Aminoglycosides; Anti-Bacterial Agents; Endocarditis; Female; Humans; Lipoglycopeptides; Middle Aged; Pacemaker, Artificial; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin